Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
REG-001
- Development stage
- Preclinical
- Lead developer
- Regenica Biosciences
- Modality
- Small Molecules
01
Overview
REG-001 is a small molecule therapeutic candidate being developed by Regenica Biosciences as an antidote for organophosphate poisoning, including exposure to chemical nerve agents and insecticides. Developed by scientific founders including Nobel laureate Barry Sharpless and Palmer Taylor, the drug is specifically engineered to cross the blood-brain barrier, a significant improvement over current standard-of-care treatments like pralidoxime (2-PAM) which have limited central nervous system penetration. By reaching the brain, REG-001 can reactivate acetylcholinesterase and prevent the life-threatening seizures and long-term neurological damage typically associated with organophosphate toxicity. The compound was in preclinical development as of 2019.
- Other names
- ReGenica
02
Targets
Acetylcholinesterase
Beyond the preview
Go deeper on REG-001.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on REG-001.